Skip to content

Mannkind MNKD Milestone Liabilities Noncurrent

Milestone Liabilities Noncurrent at other companies

Biogen logo
BiogenBIIB
$787.1M+4.7%
Moderna logo
ModernaMRNA
$283M+3.3%
Sana Biotechnology logo
Sana BiotechnologySANA
$16.93M+264%
Hilton Worldwide logo
Hilton WorldwideHLT
$977M+2.2%
AWK
American Water WorksAWK
$204M-19.0%
BG
BungeBG
$1.15B+46.1%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B-50.6%
Enterprise value$1.15B-52.2%
P/E228.5×
P/S3.3×-4.8×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:MilestoneLiabilitiesNoncurrent.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's milestone liabilities noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's milestone liabilities noncurrent?
Mannkind (MNKD) reported milestone liabilities noncurrent of $2M in Q1 2026.
How has Mannkind's milestone liabilities noncurrent changed year-over-year?
Mannkind's milestone liabilities noncurrent decreased by 20.6% year-over-year, from $2.52M to $2M.
What is the long-term trend for Mannkind's milestone liabilities noncurrent?
Over 4 years (2021 to 2025), Mannkind's milestone liabilities noncurrent has grown at a -19.8% compound annual growth rate (CAGR), from $4.84M to $2M.
What does milestone liabilities noncurrent mean?
This represents long-term obligations to make payments to third parties upon the successful completion of specific development, regulatory, or commercial milestones. These liabilities are common in biopharmaceutical licensing and collaboration agreements. They serve as an indicator of future capital requirements tied to the successful advancement of the product pipeline.